LIVE MARKETS-On our radar: virus hits hard but some earnings please

* European shares seen opening lower

* Rising U.S. virus cases and lockdowns sour mood

* Euro STOXX 50 and FTSE futures down nearly 1%
Welcome to the home for real-time coverage of markets brought to
you by Reuters reporters. You can share your thoughts with us at
markets.research@thomsonreuters.com

ON OUR RADAR: VIRUS HITS HARD BUT SOME EARNINGS PLEASE (0739
GMT)

On the corporate front there are no major market moving
updates but newsflow continues to show how the coronavirus
crisis is hitting businesses hard, even though not all earning
updates are gloomy as online orders and the stay-at-home economy
grows.

Ailing conglomerate Thyssenkrupp said it needs a
further 5,000 jobs to ease the impact of the COVID-19 crisis,
while budget airline Norwegian Air has asked an Irish
court to oversee a restructuring of its massive debt as it seeks
to stave off collapse.

Meantime the FT has reported that Cineworld is
looking at an insolvency process used to cut costs, as part of
its talks with lenders to gain access to capital.

On a more brighter note, French conglomerate Bouygues
has raised its outlook for the second half of the year
on the back of a strong Q3.

British home improvement retailer Kingfisher saw a
17% jump in quarterly underlying sales, continuing to benefit
from the popularity of do-it-yourself during the pandemic.

More online orders helped Naked Wines raise its
full-year sales forecast as H1 revenues grew nearly 80%
, while online shopping helped Royal Mail
boost sales but losses in its letters unit and virus-related
costs led to a slump in pre-tax profit.

Online trading platform CMC Markets posted a record
net operating income as the coronavirus crisis lifted volatility
in financial markets.

Chemicals maker Johnson Matthey reported a slump in
half-year profit and stayed away from providing an outlook for
2021, as the pandemic continued to dent demand.

In M&A, Swiss engineer ABB unveiled plans to
offload three business units that generate $1.75 billion in
sales.

While we're still waiting for AstraZeneca's late
stage trial results, vaccine developments continue to inspire
confidence following the Pfizer and Moderna updates.

Pfizer and BioNTech could secure
emergency U.S. and European authorization for their COVID-19
vaccine next month with first deliveries possibly before
Christmas.

(Danilo Masoni)

*****

EUROPE SEEN LOWER ON WALL STREET SLIDE (0636 GMT)

European shares could fall sharply at the open today on the
back of heavy late-session losses on Wall Street overnight as
growing COVID-19 infections and shutdowns in the world's largest
economy sour investor sentiment.

The S&P 500 closed down more than 1% yesterday as
losses accelerated after markets here in Europe closed.

The U.S. death toll from COVID-19 surpassed a grim new
milestone of 250,000 lives lost, while NY Fed's Williams said
the rapid increase in infections could hurt the economy, even
though vaccine developments made him "somewhat more optimistic".

While U.S. stock index futures are now steady after
the sell-off, early indications from European futures
point to declines of nearly 1%.

(Danilo Masoni)

*****